Sanofi Genzyme

Established in 1956, Lantheus Medical Imaging is one of the leading manufacturers of diagnostic imaging equipment and related products in the United States. Its products include xenon gas, injectable suspensions, generators, dispensing pins, injections and technetium kits. The company provides Cardiolite, which is an injection kit that is used in myocardial perfusion imaging application. It additionally offers DEFINITY, which is used in suboptimal echocardiograms. The company also supplies a variety of products under the VIALMIX, TechneLite, Neurolite and INTELLPIN brands. It provides sales, marketing, distribution, technical support, and research and development services. Lantheus Medical Imaging maintains offices in Puerto Rico, Canada and Australia.

Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous and immune systems. It provides clinical development programs for the areas of schizophrenia, obsessive-compulsive disorder, bipolar disorder, multiple sclerosis and lupus. Repligen markets two niche products, Protein A and SecreFlo. Protein A is a consumable reagent used by the pharmaceutical industry to manufacture a class of drugs called monoclonal antibodies. The company offers a number of products based on recombinant Protein A, which include recombinant Protein A, Immobilized Protein A and Protein A ELISA Kits. SecreFlo is approved by the Food and Drug Administration to aid in the diagnosis of pancreatic exocrine dysfunction and gastrinoma and to aid in the identification and cannulation of the pancreatic ducts in patients undergoing endoscopic retrograde cholangiopancreatography. Repligen Corporation was established in 1981 and is headquartered in Waltham, Mass.

Antigenics is a biotechnology company working to develop treatments for cancers, infectious diseases and autoimmune disorders. It employs more than 200 people, and has corporate offices in New York City, and research, development and manufacturing facilities in Lexington, Mass. Founded more than 10 years ago, the company has grown through the acquisition of Aronex Pharmaceuticals, a company with products that treat cancer using novel drug formulations designed to reduce toxicity and increase efficacy, and Aquila Biopharmaceuticals, with products built on an immunology technology platform.